Clinical trials
Influenza, Human trials with no applicable phase and unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2018 | 2 |
| 2019 | 2 |
| 2022 | 5 |
| 2023 | 4 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 29 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Assistance Publique - Hôpitaux de Paris | 2 |
| Tel-Aviv Sourasky Medical Center | 2 |
| The University of Hong Kong | 2 |
| Centre of Postgraduate Medical Education | 1 |
| Composite Interceptive Med Science | 1 |
| Hadassah Medical Organization | 1 |
| Insight Therapeutics, LLC | 1 |
| International Centre for Diarrhoeal Disease Research, Bangladesh | 1 |
| Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 1 |
| Kern Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Influenza, Human | 29 |
| Respiratory Tract Infections | 4 |
| COVID-19 | 3 |
| Common Cold | 2 |
| Respiratory Syncytial Virus Infections | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Arthritis, Rheumatoid | 1 |
| Bronchiolitis | 1 |
| Fibromyalgia | 1 |
| HIV Infections | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.